Translational research associated or integrated into our clinical trials aims at identification of patient subgroups responding to the treatments tested, understanding respective underlying molecular mechanisms, and discovery of new molecular targets for future therapies. All future trial designs comprise a translational research component addressing the question asked by the trial.
Recent studies carried out by the brain tumor group have provided strong clinical evidence for the prognostic or predictive value, respectively, of molecular markers tested. The important clinical impact of these findings is reflected in the fact that the markers have been implemented in the design of the respective follow-up trials. Advances in outcome prediction will lead to individualized management of patients by means of stratifying treatments according to the individual molecular profiles of the patients’ tumors.
However, in order to perform translational research, we need adequate and correctly processed material. Please see the following links for the freezing protocols:
» Protocol snap freezing of tumour biopsies
» Protocol snap freezing of lymphocytes